DK1175909T3 - Terapeutiske sammensætninger af antistoffer og antisense-nukleinsyrer mod Serrate - Google Patents
Terapeutiske sammensætninger af antistoffer og antisense-nukleinsyrer mod SerrateInfo
- Publication number
- DK1175909T3 DK1175909T3 DK01120663T DK01120663T DK1175909T3 DK 1175909 T3 DK1175909 T3 DK 1175909T3 DK 01120663 T DK01120663 T DK 01120663T DK 01120663 T DK01120663 T DK 01120663T DK 1175909 T3 DK1175909 T3 DK 1175909T3
- Authority
- DK
- Denmark
- Prior art keywords
- serrate
- protein
- nucleic acids
- fragments
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
- C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95501292A | 1992-09-30 | 1992-09-30 | |
US08/083,590 US5786158A (en) | 1992-04-30 | 1993-06-25 | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
PCT/US1993/009338 WO1994007474A1 (en) | 1992-09-30 | 1993-09-30 | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1175909T3 true DK1175909T3 (da) | 2009-07-06 |
Family
ID=26769466
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01120663T DK1175909T3 (da) | 1992-09-30 | 1993-09-30 | Terapeutiske sammensætninger af antistoffer og antisense-nukleinsyrer mod Serrate |
DK93923752T DK0662827T4 (da) | 1992-09-30 | 1993-09-30 | Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93923752T DK0662827T4 (da) | 1992-09-30 | 1993-09-30 | Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer |
Country Status (11)
Country | Link |
---|---|
US (2) | US5786158A (da) |
EP (4) | EP2145897A3 (da) |
JP (1) | JP3851653B2 (da) |
AT (2) | ATE425181T1 (da) |
AU (1) | AU685067B2 (da) |
CA (1) | CA2145778C (da) |
DE (2) | DE69334266D1 (da) |
DK (2) | DK1175909T3 (da) |
ES (2) | ES2174855T5 (da) |
PT (1) | PT662827E (da) |
WO (1) | WO1994007474A1 (da) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004924A (en) | 1991-12-11 | 1999-12-21 | Imperial Cancer Research Technology, Ltd. | Protein sequences of serrate gene products |
US5869282A (en) * | 1991-12-11 | 1999-02-09 | Imperial Cancer Research Technology, Ltd. | Nucleotide and protein sequences of the serrate gene and methods based thereon |
US20050112121A1 (en) * | 1992-04-30 | 2005-05-26 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US5786158A (en) * | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US20030225019A1 (en) * | 2002-05-30 | 2003-12-04 | Freier Susan M. | Notch1 inhibitors for inducing apoptosis |
CA2226087C (en) * | 1995-06-28 | 2012-01-31 | Imperial Cancer Research Technology, Ltd. | Nucleotide and protein sequences of vertebrate delta genes and methods based thereon |
US20050158859A1 (en) * | 1995-09-29 | 2005-07-21 | Yale University | Manipulation of non-terminally differentiated cells using the Notch pathway |
US5780300A (en) * | 1995-09-29 | 1998-07-14 | Yale University | Manipulation of non-terminally differentiated cells using the notch pathway |
PL333302A1 (en) * | 1996-11-07 | 1999-11-22 | Lorantis Ltd | Notch proteine |
US6887475B1 (en) | 1996-11-07 | 2005-05-03 | Lorantis Limited | Notch |
JP2001521382A (ja) | 1997-04-04 | 2001-11-06 | ミレニウム ファーマスーティカルズ インコーポレイテッド | 新規なヒトデルタ3組成物ならびにそれらの治療および診断への使用方法 |
US6121045A (en) * | 1997-04-04 | 2000-09-19 | Millennium Biotherapeutics, Inc. | Human Delta3 nucleic acid molecules |
US6436650B1 (en) | 1997-07-23 | 2002-08-20 | Yale University | Activated forms of notch and methods based thereon |
US6692919B1 (en) | 1997-07-23 | 2004-02-17 | Yale University | Activated forms of notch and methods based thereon |
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
AU2342299A (en) * | 1998-01-26 | 1999-08-09 | Genquest Inc. | Compositions and methods for detecting and treating breast cancer |
AU768269B2 (en) * | 1998-10-02 | 2003-12-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Apoptosis inducing agents and methods |
US8084258B2 (en) * | 1999-07-12 | 2011-12-27 | University Of Basel | Manipulation of tissue of organ type using the notch pathway |
JP2003507029A (ja) * | 1999-08-19 | 2003-02-25 | カイロン コーポレイション | Notchレセプターリガンドおよびその使用 |
US6720173B1 (en) | 1999-11-08 | 2004-04-13 | Lexicon Genetics Incorporated | Human kinase protein and polynucleotides encoding the same |
GB9927328D0 (en) | 1999-11-18 | 2000-01-12 | Lorantis Ltd | Immunotherapy |
GB9927331D0 (en) | 1999-11-18 | 2000-01-12 | Fluorescience Ltd | Assay for measuring enzyme activity in vivo |
US6159697A (en) * | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
AU2002214531A1 (en) * | 2000-07-03 | 2002-01-30 | Curagen Corporation | Proteins and nucleic acids encoding same |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US20080194022A1 (en) * | 2000-08-03 | 2008-08-14 | Clarke Michael F | Isolation and use of solid tumor stem cells |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US20020151487A1 (en) * | 2000-08-31 | 2002-10-17 | Loyola University Chicago | Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway |
WO2002059285A1 (en) * | 2000-10-27 | 2002-08-01 | Fred Hutchinson Cancer Research Center | Methods for immortalizing cells |
US6649346B2 (en) * | 2001-03-30 | 2003-11-18 | Board Of Regents, The University Of Texas | Methods of identifying agents that affect cleavage of amyloid-β precursor protein |
GB0112818D0 (en) * | 2001-05-25 | 2001-07-18 | Lorantis Ltd | Conjugate |
AU2002322264A1 (en) * | 2001-06-14 | 2003-01-02 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, bgs-8, expressed highly in immune tissue |
WO2002102987A2 (en) * | 2001-06-18 | 2002-12-27 | The General Hospital Corporation | Methods and compositions based on protein interactions with mastermind |
WO2003004645A1 (en) * | 2001-07-03 | 2003-01-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of cancer involving the notch pathway |
GB0118155D0 (en) * | 2001-07-25 | 2001-09-19 | Lorantis Ltd | Superantigen |
US20030148954A1 (en) * | 2001-11-02 | 2003-08-07 | Wisconsin Alumni Research Foundation | Agents and methods for modulating activator protein-1-mediated cellular processes |
EP1448599A2 (en) * | 2001-11-14 | 2004-08-25 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
CA2465304A1 (en) * | 2001-11-14 | 2003-05-22 | Lorantis Limited | Composition comprising inhibitors of the notch signalling pathway for the modulation of the immune system |
US20050137130A1 (en) * | 2001-11-14 | 2005-06-23 | Bodmer Mark W. | Medical treatment |
CA2468457A1 (en) * | 2001-11-29 | 2003-06-12 | Benjamin F. Cravatt | Enzyme activity profiles |
JP2005511754A (ja) * | 2001-12-07 | 2005-04-28 | リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 乳癌幹細胞の予測的同定および特徴づけ |
US20040106566A1 (en) * | 2002-05-17 | 2004-06-03 | Shi-Lung Lin | RNA-splicing and processing-directed gene silencing and the relative applications thereof |
US20040101847A1 (en) * | 2002-11-22 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of Notch2 expression |
US20040102390A1 (en) * | 2002-11-21 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of Notch3 expression |
US20050124572A1 (en) * | 2002-06-17 | 2005-06-09 | Freier Susan M. | Compositions and their uses directed to signal tranducers |
JP4558485B2 (ja) * | 2002-07-18 | 2010-10-06 | 正康 大河内 | Notch由来新規ポリペプチドおよびそれを用いたバイオマーカー並びに試薬 |
WO2004024764A1 (en) * | 2002-09-10 | 2004-03-25 | Lorantis Limited | Pharmaceutical composition and medical treatments comprising notch ligand proteins |
GB0300428D0 (en) * | 2003-01-09 | 2003-02-05 | Lorantis Ltd | Medical treatment |
GB0307472D0 (en) * | 2003-04-01 | 2003-05-07 | Lorantis Ltd | Medical treatment |
KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
US8029984B2 (en) * | 2003-08-08 | 2011-10-04 | Licentia, Ltd. | Materials and methods for colorectal cancer screening, diagnosis and therapy |
WO2005021783A2 (en) * | 2003-08-30 | 2005-03-10 | Adrian Merlo | New use of gain and loss of notch2 function in brain tumors and the new notch2 genetic alterations of the notch2 gene per se |
CA2546017A1 (en) * | 2003-11-26 | 2005-06-16 | Health Research, Inc. | Use of notch pathway interfering agents for treatment of plasma cell disorders |
JP2007526455A (ja) * | 2004-02-03 | 2007-09-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法 |
WO2006047878A1 (en) * | 2004-11-03 | 2006-05-11 | British Columbia Cancer Agency Branch | Cancer therapeutics and methods for their use |
US20060252073A1 (en) * | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
WO2006135886A2 (en) * | 2005-06-13 | 2006-12-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
AU2006259583A1 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2007053648A2 (en) | 2005-10-31 | 2007-05-10 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
ES2547421T3 (es) | 2005-10-31 | 2015-10-06 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para diagnosticar y tratar el cáncer |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
US20080019961A1 (en) * | 2006-02-21 | 2008-01-24 | Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
US20080241150A1 (en) * | 2006-05-15 | 2008-10-02 | The Brigham And Women's Hospital, Inc. | Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1 |
US7919092B2 (en) * | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
EA018260B1 (ru) | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
WO2008048680A2 (en) * | 2006-10-19 | 2008-04-24 | Maine Medical Center Research Institute | Notch 2 signaling as a breast cancer suppressor pathway |
EP2087006B1 (en) * | 2006-10-19 | 2016-06-08 | Genentech, Inc. | Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases |
AR063493A1 (es) | 2006-10-19 | 2009-01-28 | Genentech Inc | Nuevos anticuerpos anti notch 3 y su uso para la deteccion y el diagnostico de enfermedades |
WO2008076960A2 (en) | 2006-12-18 | 2008-06-26 | Genentech, Inc. | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
JP5618544B2 (ja) | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
EP2106439B1 (en) * | 2007-01-24 | 2014-11-12 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
WO2008100563A2 (en) * | 2007-02-14 | 2008-08-21 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
EP2155249A4 (en) | 2007-05-15 | 2011-11-16 | Oncomed Pharm Inc | COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER |
PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
ES2535614T3 (es) | 2008-07-08 | 2015-05-13 | Oncomed Pharmaceuticals, Inc. | Agentes de unión a Notch y antagonistas y métodos de uso de los mismos |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
NZ592338A (en) | 2008-09-26 | 2012-11-30 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
AR073717A1 (es) * | 2008-10-01 | 2010-11-24 | Genentech Inc | Anticuerpos anti-notch2 de murino y humano, y metodos de uso |
US20110286916A1 (en) * | 2008-11-20 | 2011-11-24 | Jose Miguel Aste-Amezaga | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
WO2010146550A1 (en) | 2009-06-18 | 2010-12-23 | Pfizer Inc. | Anti notch-1 antibodies |
JP5965318B2 (ja) | 2009-10-16 | 2016-08-03 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Dll4アンタゴニストおよび降圧剤の治療的併用およびそれらによる治療の方法 |
US8945569B2 (en) | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
EP2523682B1 (en) | 2010-01-13 | 2015-12-16 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
AU2011235904B2 (en) | 2010-04-01 | 2015-10-08 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
US9141756B1 (en) | 2010-07-20 | 2015-09-22 | University Of Southern California | Multi-scale complex systems transdisciplinary analysis of response to therapy |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
RU2622083C2 (ru) | 2010-12-15 | 2017-06-09 | ВАЙЕТ ЭлЭлСи | Антитела против notch1 |
HRP20230078T1 (hr) | 2011-09-23 | 2023-05-12 | Mereo Biopharma 5, Inc. | Sredstva za vezivanje vegf/dll4 i njihova uporaba |
US9266959B2 (en) | 2012-10-23 | 2016-02-23 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using frizzled-binding agents |
CA2889638A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
PE20150892A1 (es) | 2012-11-07 | 2015-06-11 | Pfizer | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco |
US9359444B2 (en) | 2013-02-04 | 2016-06-07 | Oncomed Pharmaceuticals Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
US9944700B2 (en) | 2013-03-13 | 2018-04-17 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
US20160176962A1 (en) | 2014-10-31 | 2016-06-23 | Oncomed Pharmaceuticals, Inc. | Combination Therapy For Treatment Of Disease |
CA2982169A1 (en) | 2015-04-10 | 2016-10-13 | Applied Proteomics, Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
ES2968074T3 (es) | 2015-09-23 | 2024-05-07 | Mereo Biopharma 5 Inc | Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino |
CN108472201A (zh) * | 2015-09-26 | 2018-08-31 | 财团法人卫生研究院 | 用于治疗掉发之方法及组成物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US5115096A (en) * | 1988-04-15 | 1992-05-19 | Oncogen | Amphiregulin: a bifunctional growth modulating glycoprotein |
US5132212A (en) * | 1989-11-17 | 1992-07-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Scl gene, and a hematopoietic growth and differentiation factor encoded thereby |
IL101728A (en) * | 1991-05-03 | 2007-08-19 | Univ Yale | Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them |
IE20030749A1 (en) * | 1991-05-03 | 2003-11-12 | Indiana University Foundation | Human notch and delta binding domains in torporythmic proteins, and methods based thereon |
US5264557A (en) * | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
WO1993012141A1 (en) * | 1991-12-11 | 1993-06-24 | Yale University | Nucleotide and protein sequences of the serrate gene and methods based thereon |
US5786158A (en) * | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US5780300A (en) * | 1995-09-29 | 1998-07-14 | Yale University | Manipulation of non-terminally differentiated cells using the notch pathway |
WO1997019172A1 (fr) * | 1995-11-17 | 1997-05-29 | Asahi Kasei Kogyo Kabushiki Kaisha | Polypeptide suppresseur et de differenciation |
JP2000512134A (ja) * | 1996-05-31 | 2000-09-19 | ザ ナショナル アメリカン レッド クロス | Jagged/Notchタンパク質および核酸に基づく治療および診断の方法および組成物 |
-
1993
- 1993-06-25 US US08/083,590 patent/US5786158A/en not_active Expired - Lifetime
- 1993-09-30 AT AT01120663T patent/ATE425181T1/de active
- 1993-09-30 JP JP50932694A patent/JP3851653B2/ja not_active Expired - Fee Related
- 1993-09-30 ES ES93923752T patent/ES2174855T5/es not_active Expired - Lifetime
- 1993-09-30 AU AU53503/94A patent/AU685067B2/en not_active Expired
- 1993-09-30 DE DE69334266T patent/DE69334266D1/de not_active Expired - Lifetime
- 1993-09-30 EP EP08007695A patent/EP2145897A3/en not_active Withdrawn
- 1993-09-30 PT PT93923752T patent/PT662827E/pt unknown
- 1993-09-30 WO PCT/US1993/009338 patent/WO1994007474A1/en active IP Right Grant
- 1993-09-30 CA CA2145778A patent/CA2145778C/en not_active Expired - Lifetime
- 1993-09-30 DE DE69331832T patent/DE69331832T3/de not_active Expired - Lifetime
- 1993-09-30 DK DK01120663T patent/DK1175909T3/da active
- 1993-09-30 EP EP01120662A patent/EP1197220A3/en not_active Ceased
- 1993-09-30 ES ES01120663T patent/ES2324641T3/es not_active Expired - Lifetime
- 1993-09-30 DK DK93923752T patent/DK0662827T4/da active
- 1993-09-30 EP EP93923752A patent/EP0662827B2/en not_active Expired - Lifetime
- 1993-09-30 AT AT93923752T patent/ATE216225T1/de active
- 1993-09-30 EP EP01120663A patent/EP1175909B1/en not_active Expired - Lifetime
-
1995
- 1995-09-22 US US08/532,384 patent/US6083904A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1197220A3 (en) | 2009-04-15 |
WO1994007474A1 (en) | 1994-04-14 |
DE69331832T2 (de) | 2002-12-19 |
EP1175909B1 (en) | 2009-03-11 |
JP3851653B2 (ja) | 2006-11-29 |
ES2174855T5 (es) | 2009-05-01 |
AU685067B2 (en) | 1998-01-15 |
DE69331832T3 (de) | 2009-07-16 |
CA2145778A1 (en) | 1994-04-14 |
EP1175909A2 (en) | 2002-01-30 |
DE69334266D1 (de) | 2009-04-23 |
DE69331832D1 (de) | 2002-05-23 |
ATE216225T1 (de) | 2002-05-15 |
ATE425181T1 (de) | 2009-03-15 |
ES2174855T3 (es) | 2002-11-16 |
ES2324641T3 (es) | 2009-08-12 |
PT662827E (pt) | 2002-09-30 |
EP1175909A8 (en) | 2002-08-21 |
DK0662827T3 (da) | 2002-08-12 |
CA2145778C (en) | 2012-04-17 |
EP0662827A4 (en) | 1997-12-03 |
EP2145897A3 (en) | 2010-03-03 |
EP0662827B2 (en) | 2009-01-07 |
EP0662827A1 (en) | 1995-07-19 |
US6083904A (en) | 2000-07-04 |
AU5350394A (en) | 1994-04-26 |
EP1197220A2 (en) | 2002-04-17 |
JPH08502170A (ja) | 1996-03-12 |
EP1175909A3 (en) | 2003-11-26 |
DK0662827T4 (da) | 2009-04-20 |
EP0662827B1 (en) | 2002-04-17 |
EP2145897A2 (en) | 2010-01-20 |
US5786158A (en) | 1998-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1175909T3 (da) | Terapeutiske sammensætninger af antistoffer og antisense-nukleinsyrer mod Serrate | |
PT737207E (pt) | Inibidores de plasmina humana derivados de dominios kunitz | |
DE68929430D1 (de) | Fibronektin bindendes Protein | |
DE69435049D1 (de) | Chimäre proteine zur vermeidung der komplementaktivierung | |
NO964650L (no) | LAG-3 proteinopploselige polypeptidfraksjoner, fremgangsmate for fremstilling, terapeutisk preparat og anti-idiotype antistoff | |
IL92257A0 (en) | Binding proteins for insulin-like growth factors,pharmaceutical compositions containing them and dna fragments encoding them | |
EP0422125A4 (en) | Platelet blocking peptides | |
AU3793493A (en) | Therapeutic domains of von willebrand factor | |
ES2010283A6 (es) | Procedimiento para preparar derivados de somatostatina. | |
SE8801723D0 (sv) | Fibronectin binding protein as well as its preparation | |
HU896448D0 (en) | Process for the preparation of anticoagulant peptides | |
PT866861E (pt) | Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina | |
WO2002036628A3 (en) | New multimeric interferon beta polypeptides | |
TR200002611T2 (tr) | Beta-lipotropin ve kullanımları | |
EP0367641A3 (en) | Lymphokines, dna sequences encoding these lymphokines and pharmaceutical compositions containing these lymphokines |